ReviewMolecular oncology2012
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
Review in Molecular oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Critical reviews in oncology/hematology · 2013Pooled it
- Effect of personalized care based on OPT model on perceived control and quality of life among patients with breast cancer.Frontiers in public health · 2023Trial
- Review
- The impact of systemic and radiation therapy in patients undergoing spine surgery for metastatic breast cancer: a dual-institution study.Journal of neurosurgery. Spine · 2025Article
- Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling.Frontiers in immunology · 2025Review
- Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment.Metabolites · 2024Review
- Review
- Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.Nutrients · 2024Review
- Review
- Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.BMC molecular and cell biology · 2024Article
- Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.Galen medical journal · 2024Article
- Targeting sex steroid biosynthesis for breast and prostate cancer therapy.Nature reviews. Cancer · 2023Review
- Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.Biomolecules · 2023Review
- Unveiling the Role of Hormonal Imbalance in Breast Cancer Development: A Comprehensive Review.Cureus · 2023Review
- Tamoxifen decreases ovarian toxicity without compromising cancer treatment in a rat model of mammary cancer.BMC genomics · 2023Article
- Avicularin Alleviates Osteoporosis in Ovariectomized Mice by Inhibiting Osteoclastogenesis through NF-κB Pathway Inhibition.Journal of agricultural and food chemistry · 2023Article
- Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation.International journal of molecular sciences · 2022Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.